pharmaceutical

Big Pharma Eyes Cannabis as Schedule III Move Draws New Investment

Pharmaceutical companies and institutional investors are reassessing cannabis opportunities as federal rescheduling advances, potentially bringing new capital but also competition to the marijuana industry.